Saturday 17 October 2026
Export INGN’s income statement to Excel — free account
Inogen, Inc
INGN Healthcare Medical Devices
Inogen, Inc’s revenue for fiscal 2025 (year ended December 2025) was $348.7 million, up 3.86% from fiscal 2024. In the quarter to June 2026, revenue grew 3.04%, EPS grew 6.67% and free cash flow fell 51.2%, each against the same quarter a year earlier.
6.25
0.05
−0.79%
Follow INGN
Inogen, Inc (INGN) P/E ratio
Inogen, Inc has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 186× (September 2018) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 71.2× | 39.87% |
| FY2018 | 50.9× | (56.87%) |
| FY2017 | 118× | 82.75% |
| FY2016 | 64.6× | (3.37%) |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 42 more quarters | Free account |
Against its own ten years
Low 0.0×
High 186×
Ten-year median
24.5×
Current reading's percentile
49
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| MXCT MaxCyte, Inc. compare | n/m |
| OWLT Owlet, Inc. compare | n/m |
| RXST RxSight, Inc. compare | n/m |
| INGN Inogen, Inc | n/m |
| STIM Neuronetics, Inc. compare | n/m |
| TLSI TriSalus Life Sciences, Inc. compare | n/m |
| QTRX Quanterix Corporation compare | n/m |
| PROF Profound Medical compare | n/m |
| ELMD Electromed, Inc. compare | 20.0× |
| Medical Devices industry median | 23.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)